DelveInsight
DelveInsight's primary conduit for delivering intelligent information to professionals in both the business and healthcare sectors is through its meticulously crafted analytical and strategic reports. Presently, DelveInsight boasts a diverse portfolio encompassing over 3,000 Marketed and Pipeline Reports. These reports are thoughtfully categorized based on parameters such as indication, mechanism of actions, drugs, global API manufacturers, and specialized reports focusing on pivotal areas such as Onco-Immunology, Orphan Diseases, Biologics & Biosimilars, Gene Therapy, Stem Cells Therapy, and other emerging domains. This robust platform has become the go-to resource for numerous enterprises seeking to transform and redefine their business strategies.
DelveInsight's offerings extend beyond reports to encompass Consulting Projects and Competitive Intelligence services, catering to the multifaceted needs of its clientele. Moreover, the organization is dedicated to providing tailor-made research services that align with the specific interests and requirements of its clients. DelveInsight's commitment to excellence and innovation positions it as a trusted partner in the areas of business strategy and market research.
View recent articles by this publisher on our blog:
4 Blockbuster Drugs to Watch for Non-Small Lung Cancer (NSCLC)
The Power of Digital Therapeutics in Mental Health
Anti-VEGF Therapies: Forever Market Rulers of Wet-AMD Treatment?
Additional articles from this publisher
10,954 Reports from DelveInsight
-
Chronic Spontaneous Urticaria - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights According to DelveInsight’s analysis, the Chronic Spontaneous Urticaria Market Size in the 7MM was valued at approximately USD 2,173.3 million in 2023. Over the forecast period from 2024 to 2034, this market is projected to grow at a CAGR of more than 10%, driven by the introduction o ... Read More
-
Acromegaly- Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights According to the estimates, the Acromegaly market size in the 7MM is ~USD 1,300 million in 2023. In 2023, among all the therapies, the highest Acromegaly market revenue was generated by somatostatin, i.e., ~USD 300 million, followed by growth hormone antagonist, i.e., ~USD 90 million ... Read More
-
Ewing Sarcoma - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the US accounted for the maximum share of the Ewing sarcoma Treatment Market in the 7MM, i.e., nearly 53%. A molecular-targeted therapy with minimal risk of late toxicities would be beneficial because most Ewing sarcoma Patients are under 20 years old. Although there is no st ... Read More
-
Epidermolysis Bullosa - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the market size of epidermolysis bullosa was highest in the US among the 7MM, accounting for approximately USD 1,300 million, which is further expected to increase by 2034. Epidermolysis bullosa simplex (EBS) is the least severe type of epidermolysis bullosa, and many individ ... Read More
-
Alzheimer's Disease - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the 7MM reported approximately 15,840 thousand diagnosed prevalent cases of Alzheimer’s disease, reflecting a significant disease burden. This high prevalence underscores the need for innovative treatments to address the rising impact on healthcare systems and patient care. I ... Read More
-
Heparin-induced Thrombocytopenia - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights The heparin-induced thrombocytopenia market size in the 7MM is estimated to be around ~USD 128 million, in 2023. Heparin-induced thrombocytopenia is characterized by a rapid decrease in platelet count occurring 5–14 days after the initiation of heparin therapy. It is primarily caused ... Read More
-
KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034
Key Highlights Among the 7MM, the United States captured the highest KRAS inhibitors market size in 2023, accounting for nearly 70% of the total KRAS Inhibitor market share. Among the approved KRAS Inhibitor therapies in the United States, KRAZATI is expected to have the edge over LUMAKRAS in revenu ... Read More
-
Oligometastatic Disease - Market Insights, Epidemiology, and Market Forecast - 2034
Key Highlights According to DelveInsight’s patient-based forecasting model, the oligometastatic disease market size in the 7MM was around USD 1,900 million in 2023, which is expected to significantly increase over the forecast period (2024-2034), owing to an increase in the cases and the launch of n ... Read More
-
Postpartum Depression - Market Insights, Epidemiology, and Market Forecast - 2034
Key Highlights The Postpartum Depression Treatment Market Size in the 7MM was estimated to be USD 260 million in 2023. Among EU4 and the UK, the UK accounted for the highest Postpartum Depression Market Size of ~USD 25 Million in 2023. Among the seven major countries, the Postpartum Depression diagn ... Read More
-
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2025
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview ""Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Renal Failure (ARF) (Acute Kidney I ... Read More
-
Actinic keratosis - Pipeline Insight, 2025
DelveInsight’s, “Actinic keratosis - Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Actinic keratosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therape ... Read More
-
Anaplastic astrocytoma - Pipeline Insight, 2025
DelveInsight’s, “Anaplastic astrocytoma - Pipeline Insight, 2025,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Anaplastic astrocytoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers t ... Read More
-
Ankylosing Spondylitis - Pipeline Insight, 2025
DelveInsight’s, “Ankylosing Spondylitis - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Ankylosing Spondylitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers th ... Read More
-
Anthrax - Pipeline Insight, 2025
DelveInsight’s, “Anthrax - Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anthrax pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by ... Read More
-
B-cell Lymphoma- Pipeline Insight, 2025
DelveInsight’s, “B-cell Lymphoma- Pipeline Insight, 2025” report provides comprehensive insights about 295+ companies and 300+ pipeline drugs in B-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutic ... Read More
-
Bladder Pain - Pipeline Insight, 2025
Bladder Pain Overview ""Bladder Pain Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Bladder Pain market. A detailed picture of the Bladder Pain pipeline landscape is provided, which includes the ... Read More
-
Biliary Tumor - Pipeline Insight, 2025
DelveInsight’s, “Biliary Tumor - Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Biliary Tumor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics ass ... Read More
-
Bronchiectasis - Pipeline Insight, 2025
DelveInsight’s, “Bronchiectasis - Pipeline Insight, 2025,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics ... Read More
-
Bronchopulmonary Dysplasia - Pipeline Insight, 2025
DelveInsight’s, “Bronchopulmonary Dysplasia - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also c ... Read More
-
Chemotherapy Induced Peripheral Neuropathy- Pipeline Insight, 2025
DelveInsight’s, “Chemotherapy Induced Peripheral Neuropathy- Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 11+ pipeline drugs in Chemotherapy Induced Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and noncli ... Read More
-
Chronic Stable Angina - Pipeline Insight, 2025
Chronic Stable Angina Overview ""Chronic Stable Angina Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Chronic Stable Angina market. A detailed picture of the Chronic Stable Angina pipeline landsc ... Read More
-
Cirrhosis- Pipeline Insight, 2025
DelveInsight’s, “Cirrhosis- Pipeline Insight, 2025,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment ... Read More
-
Cluster Headache Syndrome- Pipeline Insight, 2025
DelveInsight’s, “Cluster Headache Syndrome- Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cluster Headache Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers ... Read More
-
Cutaneous Lupus Erythematosus – Pipeline Insight, 2025
DelveInsight’s, “Cutaneous Lupus Erythematosus – Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Cutaneous Lupus Erythematosus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It ... Read More
-
Coronary Artery Disease - Pipeline Insight, 2025
DelveInsight’s, “Coronary Artery Disease - Pipeline Insight, 2025,” report provides comprehensive insights about 30+ companies and 25+ pipeline drugs in Coronary Artery Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers ... Read More
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook